Ryan Schulz

Prior to joining the Volastra team, Ryan was at Black Diamond Therapeutics for 3.5 years, where he helped bring BDTX-4933, a reversible, brain-penetrant pan-RAF inhibitor, to IND-enabling preclinical studies. He also contributed to the implementation of a nascent large molecule program at BDTX using engineered cell lines expressing various wild type and mutant receptors.

Before his employment at BDTX, Ryan worked at Alexion Pharmaceuticals in the Protein Biochemistry group purifying and characterizing various antibodies and fusion proteins. His work there was critical for the discovery and development of two fusion proteins currently in clinical trials. Additionally, Ryan has experience at Coferon Inc., OSI/Astellas Pharmaceuticals, Enzo Life Sciences, and Brookhaven National Laboratory. He has a bachelor’s degree from Fairleigh Dickinson University and master’s degree from the University of Alabama at Birmingham.